Find Clinical Trial

Phase I/II study of oral administration of S 49076 given in combination with gefitinib in patients with EGFR mutated advanced non-small-cell lung cancer who have progressed after treatment with EGFR tyrosine kinase inhibitor.


← Back
Study Phase

Phase 1-2

Therapeutic Area

Cancers

Active substance/
Medical device

S049076

SponsorLaboratorios Servier S.L.
Active Substance CodeS049076
Protocol CodeCL1-49076-003
EudraCT Code2015-002646-31


Documents and links

Results summary READ MORE




Servier Glossary of Terms

To ease the reading, we are developing a glossary of terms. In this glossary, we provide the lay terms used in our lay summaries and the corresponding medical terms. You will find the Servier Glossary of Terms on this link.



© 2017 LES LABORATOIRES SERVIER, an incorporated company of Servier.
All Rights Reserved. Servier does not sell its products over the Internet.
More information

Report a side-effect with a drug.
Accessibility